INTRODUCTION AND OBJECTIVES: Metabolomics offers the ability to exploit the unique metabolic dysregulation inherent in known pathways of renal cell carcinoma pathogenesis to help guide clinical management. While metabolomic pathways and signatures have been studied of a variety of cancers, the signature of urine of patients with RCC has not been well established. We consequently interrogated distinct urinary pathway-level metabolic shifts in patients following surgical excision of renal masses to differentiate metabolic profiles of highrisk clear cell RCC (ccRCC) from indolent and benign tumors.
METHODS: Patients undergoing surgery for non-metastatic RCC were enrolled in an IRB-approved, institutional biorepository and donated urine samples prior to surgery. Patients 0 pathology was indexed as high-risk (HR), defined as high-grade (Grade III-IV) and/or locally-advanced (pT3 or higher) ccRCC; indolent, defined as pT1-T2 and low-grade (Grade I-II) ccRCC; or benign. Capillary electrophoresis mass spectrometry was utilized to process urine samples in a highthroughput fashion to identify distinctive metabolomic profiles indicative of the three pathologies. Sixty-nine targeted metabolites were detected and quantified; principal components analysis and heatmaps were generated. Differences were analyzed using Welch 0 s t-test. RESULTS: A total of 66 urine specimens were included in our analysis: 30 (45.4%) were from patients with HR RCC, 19 (28.8%) from patients with indolent disease, and 17 (25.8%) from patients with benign pathology. Patients with indolent lesions had higher concentrations of the following unique amino acids compared to benign lesions (p<0.01): Phe (þ42.4%), Tyr (þ52.2%), Trp (þ42.7%) and Lys (þ66%). Concentrations of several unique metabolites differed between benign and HR RCC lesions (p<0.01): Hypoxanthine (-42%), Threonic Acid (þ26%), EAP (þ133%), and Glycerol-3-phosphate (þ110%). HR RCC had smaller concentrations of the following metabolites versus indolent lesions (p<0.01): Betaine (-63%), Hydrouracil (-36%), N-Ac Gln (-56%), Histidine (-42%), and 2-aminoisobutyrate (-47%).
CONCLUSIONS: Given the prevalent metabolic rearrangements in RCC, use of urinary metabolomics represents a promising biomarker that can not only distinguish ccRCC from benign tumors, but also risk-stratify dangerous cancers from indolent ones by identifying specific metabolic profiles.
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Yoshiyuki Yamamoto*, Motohide Uemura, Kosuke Nakano, Yujiro Hayashi, Cong Wang, Yu Ishizuya, Kyosuke Matsuzaki, Takuji Hayashi, Toshiro Kinouchi, Kentaro Jingushi, Taigo Kato, Atsunari Kawashima, Takeshi Ujike, Akira Nagahara, Kazutoshi Fujita, Ryoichi Imamura, Norio Nonomura, Suita City, Japan INTRODUCTION AND OBJECTIVES: Reliable biomarkers for renal cell carcinoma (RCC) have yet to be found. Recently, circulating cell-free DNA (cfDNA) is getting more attention as an emerging biomarker for several types of cancer. The aim of this study is deciphering the characteristics of cfDNA in RCC patients as novel blood biomarkers.
METHODS: Plasma cfDNA was extracted from RCC patients (n ¼ 92) and healthy controls (n ¼ 41). Absolute copy number of cfDNA was determined using quantitative real-time PCR of ACTB as the target gene. We also measured the fragment size of cfDNA using a microfluidics-based platform. Diagnostic capability of these markers was assessed using receiver operating characteristic (ROC) and logistic regression analysis. Log rank test was used for comparison of prognosis between patients having shorter ( 166 bp) or longer (>166 bp) fragment size of cfDNA.
RESULTS: Mean absolute copy numbers of cfDNA in RCC patients were significantly higher than those in healthy controls (5176 vs 2584 copies/ml, p < 0.001). Mean fragment sizes of cfDNA in RCC patients were shorter than those in healthy controls (168.4 vs 171.4 bp, p ¼ 0.052). ROC curve analysis revealed that absolute copy number of cfDNA had a sensitivity of 63.0% and a specificity of 78.1% for the presence of RCC (area under the curve ¼ 0.762, p < 0.001). Multivariate analysis indicated that age, gender and absolute copy number of e1198 THE JOURNAL OF UROLOGY â Vol. 199, No. 4S, Supplement, Monday, May 21, 2018 
